Cargando…
Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy
INTRODUCTION/AIMS: Due to muscular weakness and cardiopulmonary dysfunction, patients with muscular dystrophy (MD) have an increased risk of serious complications from coronavirus disease‐2019 (COVID‐19). Although vaccination is recommended, COVID‐19 vaccination safety and immunogenicity in these pa...
Autores principales: | Saito, Tomoko, Saito, Toshio, Hashimoto, Hiroya, Ogata, Katsuhisa, Kobayashi, Michio, Takada, Hiroto, Kuru, Satoshi, Kimura, Takashi, Nakamura, Akinori, Matsumura, Tsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878062/ https://www.ncbi.nlm.nih.gov/pubmed/36478587 http://dx.doi.org/10.1002/mus.27761 |
Ejemplares similares
-
Questionnaire survey on the impact of coronavirus disease 2019 on patients with muscular dystrophy
por: Matsumura, Tsuyoshi, et al.
Publicado: (2021) -
A web-based questionnaire survey on the influence of coronavirus disease-19 on the care of patients with muscular dystrophy
por: Matsumura, Tsuyoshi, et al.
Publicado: (2021) -
Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study
por: Matsumura, Tsuyoshi, et al.
Publicado: (2022) -
Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
por: Komaki, Hirofumi, et al.
Publicado: (2020) -
A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy
por: Matsumura, Tsuyoshi, et al.
Publicado: (2017)